These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32523894)

  • 21. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2.
    Silberstein C; Lucero MS; Zotta E; Copeland DP; Lingyun L; Repetto HA; Ibarra C
    Pediatr Res; 2011 May; 69(5 Pt 1):390-4. PubMed ID: 21270676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
    Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
    J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction by sphingomyelinase of shiga toxin receptor and shiga toxin 2 sensitivity in human microvascular endothelial cells.
    Obrig TG; Seaner RM; Bentz M; Lingwood CA; Boyd B; Smith A; Narrow W
    Infect Immun; 2003 Feb; 71(2):845-9. PubMed ID: 12540565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of Shiga toxin receptor CD77/Gb3 and interleukin-1β expression in the brain of EHEC patients with hemolytic uremic syndrome and neurologic symptoms.
    Hagel C; Krasemann S; Löffler J; Püschel K; Magnus T; Glatzel M
    Brain Pathol; 2015 Mar; 25(2):146-56. PubMed ID: 24989888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of renal damage caused by Shiga toxin type 2: Action of Miglustat on human endothelial and epithelial cells.
    Girard MC; Sacerdoti F; Rivera FP; Repetto HA; Ibarra C; Amaral MM
    Toxicon; 2015 Oct; 105():27-33. PubMed ID: 26335361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e.
    Keusch GT; Jacewicz M; Acheson DW; Donohue-Rolfe A; Kane AV; McCluer RH
    Infect Immun; 1995 Mar; 63(3):1138-41. PubMed ID: 7868240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.
    Samuel JE; Perera LP; Ward S; O'Brien AD; Ginsburg V; Krivan HC
    Infect Immun; 1990 Mar; 58(3):611-8. PubMed ID: 2155181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin.
    Louise CB; Kaye SA; Boyd B; Lingwood CA; Obrig TG
    Infect Immun; 1995 Jul; 63(7):2766-9. PubMed ID: 7790096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin
    Feitz WJC; Bouwmeester R; van der Velden TJAM; Goorden S; Licht C; van den Heuvel LPJW; van de Kar NCAJ
    Microorganisms; 2021 Oct; 9(10):. PubMed ID: 34683478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells.
    Tesh VL; Samuel JE; Perera LP; Sharefkin JB; O'Brien AD
    J Infect Dis; 1991 Aug; 164(2):344-52. PubMed ID: 1649877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.
    Obrig TG
    Toxins (Basel); 2010 Dec; 2(12):2769-2794. PubMed ID: 21297888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
    Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP
    Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.
    Karpman D; Tati R
    Kidney Int; 2016 Oct; 90(4):726-9. PubMed ID: 27633864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins.
    Neri P; Nagano SI; Yokoyama S; Dohi H; Kobayashi K; Miura T; Inazu T; Sugiyama T; Nishida Y; Mori H
    Microbiol Immunol; 2007; 51(6):581-92. PubMed ID: 17579269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue-resident macrophages mediate neutrophil recruitment and kidney injury in shiga toxin-induced hemolytic uremic syndrome.
    Lill JK; Thiebes S; Pohl JM; Bottek J; Subramaniam N; Christ R; Soun C; Gueler F; Zwanziger D; Hoffmann F; von Eggeling F; Bracht T; Sitek B; Hickey MJ; Hofnagel O; Engel DR
    Kidney Int; 2021 Aug; 100(2):349-363. PubMed ID: 33930412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.
    Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S
    Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
    J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of SYS1 as a Host Factor Required for Shiga Toxin-Mediated Cytotoxicity in Vero Cells.
    Sakuma C; Sekizuka T; Kuroda M; Hanada K; Yamaji T
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles.
    Ståhl AL; Arvidsson I; Johansson KE; Chromek M; Rebetz J; Loos S; Kristoffersson AC; Békássy ZD; Mörgelin M; Karpman D
    PLoS Pathog; 2015 Feb; 11(2):e1004619. PubMed ID: 25719452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escherichia coli Shiga toxin.
    Nakao H; Takeda T
    J Nat Toxins; 2000 Aug; 9(3):299-313. PubMed ID: 10994531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.